PAH Specific Neutra™ Antibody Products

Are prolonged drug development cycles or challenges in antibody validation hindering your progress? Creative Biolabs' PAH specific Neutra™ antibodies leverage innovative protein engineering and high-throughput screening to enable rapid, reliable detection and neutralization of PAH-protein adducts, streamlining therapeutic discovery.

Introduction to PAH

Polycyclic aromatic hydrocarbons (PAH) are ubiquitous environmental pollutants formed during incomplete combustion of organic matter. Structurally, these lipophilic compounds consist of fused aromatic rings, enabling them to intercalate into cellular membranes and DNA. PAH metabolism generates reactive electrophilic intermediates, which form covalent adducts with proteins and nucleic acids, driving mutagenesis and cellular dysfunction.

• Structural Dynamics

PAH compounds exhibit planar, multi-ring configurations (e.g., benzo[a]pyrene with five rings), which dictate their binding affinity to cellular targets. The planar geometry facilitates interactions with aryl hydrocarbon receptor (AhR) and DNA base pairs, while substitutions (e.g., methyl groups) modulate toxicity and bioaccumulation.

• Associated Signaling Pathways

PAH toxicity is mediated through AhR activation, triggering cytochrome P450 enzymes (CYP1A1/1B1) to metabolize PAH into reactive diol epoxides. These intermediates induce oxidative stress via ROS generation and disrupt Nrf2-mediated antioxidant responses. Concurrently, PAH-protein adducts activate NF-κB, promoting pro-inflammatory cytokine release and sustained tissue damage.

Fig.1 Toxic mechanism of PAHs in the aquatic ecosystem.¹

• Disease Implications

Chronic PAH exposure is epidemiologically linked to lung cancer, cardiovascular diseases, and autoimmune disorders. Benzo[a]pyrene, a prototypical PAH, is classified as a Group 1 carcinogen due to its role in inducing DNA adducts and somatic mutations in TP53 and KRAS oncogenes.

Applications of PAH-Specific Neutralizing Antibodies

• Therapeutic Development

PAH-neutralizing antibodies serve as critical tools for identifying drug candidates that disrupt PAH metabolism or adduct formation. By targeting adduct-specific epitopes, these antibodies enable preclinical validation of compounds designed to reduce PAH bioavailability or enhance detoxification.

• Environmental and Clinical Diagnostics

Our antibodies enable rapid detection of PAH adducts in environmental samples (e.g., air particulate matter) and patient sera. This supports risk assessment in occupational health and early diagnosis of exposure-related pathologies, such as premalignant lung lesions.

• Mechanistic Studies of Toxicity

Researchers utilize these antibodies to visualize PAH adduct distribution in tissues, clarifying their role in organ-specific damage. Co-localization studies with AhR or NF-κB further elucidate cross-talk between metabolic activation and inflammatory cascades.

• Vaccine Efficacy Evaluation

In vaccine development, anti-PAH antibodies assess immune responses to PAH-conjugate vaccines, which aim to stimulate antibody-mediated clearance of PAH before cellular internalization.

Our Anti-PAH Neutralizing Antibodies

Creative Biolabs' PAH specific antibodies are engineered to recognize PAH-protein adducts with exceptional specificity, enabling researchers to:

- Quantify PAH adducts in biological samples with femtomolar sensitivity.

- Block PAH-AhR binding to mitigate downstream toxic signaling.

- Facilitate high-content screening for therapeutic candidates targeting PAH detoxification pathways.

These antibodies are validated for reproducibility across ELISA, immunohistochemistry (IHC), and flow cytometry, ensuring robust performance in diverse experimental workflows.

Creative Biolabs' PAH specific Neutra™ antibodies empower researchers to overcome barriers in toxicology and drug discovery with precision-driven solutions. Engineered for sensitivity and versatility, these tools are indispensable for advancing PAH-related research and therapeutic innovation.

Contact our scientific team today to explore custom solutions for your project.

REFERENCE

1. Honda, Masato, and Nobuo Suzuki. "Toxicities of polycyclic aromatic hydrocarbons for aquatic animals." International journal of environmental research and public health 17.4 (2020): 1363. Distributed under Open Access license CC BY 4.0, without modification. https://doi.org/10.3390/ijerph17041363